STOCK TITAN

Roche Holding AG - RHHBY STOCK NEWS

Welcome to our dedicated news page for Roche Holding (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roche Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roche Holding's position in the market.

Rhea-AI Summary
Roche's Elecsys pTau217 plasma biomarker test, developed in partnership with Eli Lilly and Company, receives Breakthrough Device Designation from the FDA. The test aims to identify amyloid pathology, aiding in early and accurate Alzheimer's diagnosis, potentially improving patient care and access to therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Roche receives CE Mark approval for VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx to identify metastatic breast cancer patients with low HER2 expression, potentially benefiting from ENHERTU treatment. The test aids in assessing HER2-low status, expanding treatment options for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary
Roche's cobas Malaria test receives FDA approval for screening U.S. blood donors, offering a sensitive solution to detect Plasmodium parasites and improve blood safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
News
Rhea-AI Summary
Roche shareholders approve all Board proposals, re-elect Severin Schwan as Chairman, and increase dividend for the 37th consecutive year. The company reports strong performance in Pharmaceuticals and Diagnostics Divisions with a focus on oncology, immunology, neurology, and new areas like obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
-
Rhea-AI Summary
Roche introduces navify Analytics and Monitoring solutions for laboratories and point of care services, aiming to enhance operational efficiency and financial outcomes. The suite offers actionable insights to improve productivity, reduce costs, and optimize test turnaround times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
-
Rhea-AI Summary
Roche and Alnylam's Phase II KARDIA-2 study of zilebesiran for hypertension met its primary endpoint, showing significant blood pressure reductions. The study demonstrated promising safety and tolerability, supporting potential twice-yearly dosing. The companies have initiated the Phase II KARDIA-3 study. Hypertension is a global health crisis with high mortality rates, affecting one in three adults worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
Rhea-AI Summary
Roche's Xolair shows promising results in treating food allergies in NIH-sponsored Phase III study, leading to FDA approval for expanded use in children and adults. The study reveals increased tolerance to peanuts, tree nuts, egg, milk, and wheat in multi-food allergic patients as young as 1 year old, reducing the risk of severe allergic reactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Genentech, a member of the Roche Group, has received FDA approval for Xolair to reduce allergic reactions in patients with IgE-mediated food allergy. The approval is based on positive data from the NIH-sponsored Phase III OUtMATCH study, showing improved tolerance to food allergens in patients as young as 1 year old.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
-
Rhea-AI Summary
Roche (RHHBY) partners with PathAI to develop AI digital pathology algorithms for companion diagnostics, aiming to advance precision medicine. The collaboration will enhance patient access to targeted treatments by integrating AI-interpretation into pathology labs globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
Rhea-AI Summary
Genentech, a member of the Roche Group, announced new 72-week data from two global Phase III studies evaluating Vabysmo in macular edema due to branch and central retinal vein occlusion. The data showed that nearly 60% of people receiving Vabysmo were able to extend their treatment intervals to three or four months apart. Patients maintained vision gains and retinal drying for more than one year. Vabysmo is approved in the U.S. and more than 90 countries for people with wet AMD and DME.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
Roche Holding AG

OTC:RHHBY

RHHBY Rankings

RHHBY Stock Data

199.33B
727.48M
0.16%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Basel